… demonstrated that maintenance therapy with erlotinib after … ) of non-small cell lung cancer
(NSCLC) patients with advanced, … tolerability of erlotinib maintenance in daily clinical practice. …

… that there is no discernible maintenance treatment effect in patients with EGFR wild-type
tumors for inhibition of EGFR by erlotinib when patients have a response or disease control after …

… in combining erlotinib with a biologic therapeutic agent rather … the combination of erlotinib
and bevacizumab revealed activity … erlotinib alone with erlotinib plus bevacizumab in patients …

… This study compared maintenance linsitinib plus erlotinib vs erlotinib plus placebo in patients
with … Linsitinib maintenance therapy added to erlotinib did not improve PFS or OS in non-…

… is the second most common histological subtype of non-small cell lung cancer (NSCLC) after
adenocarcinoma, … aged <65 years, and patients who did not receive maintenance therapy. …

… In addition, patients must have progressed on erlotinib and stopped erlotinib treatment for
≤… : no prior treatment with any EGFR inhibitor other than erlotinib, measurable disease per …

… -line and maintenance therapy within patient groups. Literature … with erlotinib maintenance
was the only treatment which … chemotherapy + erlotinib with erlotinib maintenance showed the …

… maintenance with erlotinib maintenance in non squamous non Epidermal Growth Factor
Receptor (EGFR) mutated non small cell lung cancer (… pemetrexed and erlotinib maintenance. …

… with advanced non-small cell lung cancer (NSCLC) has … /day of erlotinib seems too toxic as
maintenance therapy. This … of low-dose erlotinib (25 mg/day) as maintenance treatment after …

… 1.0 in the erlotinib plus fulvestrant arm versus erlotinib alone arm. Secondary objectives
included PFS, OS, and characterization of toxicities and identification of patient subgroups that …